Leveraging Bi-& Tri-Specific Antibodies for a Deep & Targeted Immune Reset
- Understanding the mechanism of action for bi- and tri-specific antibodies enhancing cytotoxicity and phagocytosis through forced proximity for B-cell depletion
- Exploring how multi-specificity can overcome therapeutic resistance by targeting multiple antigens across the B-cell lineage
- Managing CRS risk for CD3 engagement in non-oncology populations in non-IgG-like multi-specific antibody constructs